Gd(iii)-Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy

被引:31
作者
Adams, Casey J. [1 ,2 ,3 ,4 ]
Meade, Thomas J. [1 ,2 ,3 ,4 ]
机构
[1] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA
[2] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA
[3] Northwestern Univ, Dept Neurobiol, Evanston, IL 60208 USA
[4] Northwestern Univ, Dept Radiol, Evanston, IL 60208 USA
关键词
CISPLATIN-RESISTANCE; PLATINUM(IV) PRODRUG; COMPLEXES; DELIVERY; DRUGS; DNA;
D O I
10.1039/c9sc05937g
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Pt(iv) prodrugs have emerged as versatile therapeutics for addressing issues regarding off-target toxicity and the chemoresistance of classic Pt(ii) drugs such as cisplatin and carboplatin. There is significant potential for Pt(iv) complexes to be used as theranostic agents, yet there are currently no reported examples of Gd(iii)-Pt(iv) agents for simultaneous MR imaging and chemotherapy. Here we report the synthesis, characterization, and in vitro efficacy of two Gd(iii)-Pt(iv) agents, GP1 and GP2. Both agents are water soluble and stable under extracellularly relevant conditions but are reduced under intracellular conditions. Both are cytotoxic in multiple cancer cell lines, cell permeable, and significantly enhance the T-1-weighted MR contrast of multiple cell lines. Thus, GP1 and GP2 are promising agents for tandem MR imaging and chemotherapy and provide a versatile platform through which future Gd(iii)-Pt(iv) agents can be developed.
引用
收藏
页码:2524 / 2530
页数:7
相关论文
共 45 条
[1]   Drug Delivery Strategies for Platinum-Based Chemotherapy [J].
Browning, Richard J. ;
Reardon, Philip James Thomas ;
Parhizkar, Maryam ;
Pedley, R. Barbara ;
Edirisinghe, Mohan ;
Knowles, Jonathan C. ;
Stride, Eleanor .
ACS NANO, 2017, 11 (09) :8560-8578
[2]   A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer [J].
Chen, Hong ;
Wang, Xinyi ;
Gou, Shaohua .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2019, 193 :133-142
[3]   Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells [J].
Coen, Katrijn ;
Flannagan, Ronald S. ;
Baron, Szilvia ;
Carraro-Lacroix, Luciene R. ;
Wang, Dong ;
Vermeire, Wendy ;
Michiels, Christine ;
Munck, Sebastian ;
Baert, Veerle ;
Sugita, Shuzo ;
Wuytack, Frank ;
Hiesinger, Peter Robin ;
Grinstein, Sergio ;
Annaert, Wim .
JOURNAL OF CELL BIOLOGY, 2012, 198 (01) :23-35
[4]   Cisplatin in cancer therapy: Molecular mechanisms of action [J].
Dasari, Shaloam ;
Tchounwou, Paul Bernard .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 740 :364-378
[5]   Particular aspects of platinum compounds used at present in cancer treatment [J].
Desoize, B ;
Madoulet, C .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 42 (03) :317-325
[6]   Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets [J].
Farrell, N. P. .
CHEMICAL SOCIETY REVIEWS, 2015, 44 (24) :8773-8785
[7]   Glutathione: Overview of its protective roles, measurement, and biosynthesis [J].
Forman, Henry Jay ;
Zhang, Hongqiao ;
Rinna, Alessandra .
MOLECULAR ASPECTS OF MEDICINE, 2009, 30 (1-2) :1-12
[8]   Systems biology of cisplatin resistance: past, present and future [J].
Galluzzi, L. ;
Vitale, I. ;
Michels, J. ;
Brenner, C. ;
Szabadkai, G. ;
Harel-Bellan, A. ;
Castedo, M. ;
Kroemer, G. .
CELL DEATH & DISEASE, 2014, 5 :e1257-e1257
[9]   Clinical perspectives on platinum resistance [J].
Giaccone, G .
DRUGS, 2000, 59 (Suppl 4) :9-17
[10]   The molecular perspective: Cisplatin [J].
Goodsell, David S. .
STEM CELLS, 2006, 24 (03) :514-515